Publications
410
Citations
39,551
Est. group size
~7
Recurring co-author estimate
Active years
52
Publishing since 1974
Typically publishes in teams of ~10 · 11% small-team papers (≤3 authors) · across 28 venues
- Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Diabetes Obesity and Metabolism · 2023
- Adipose tissue from subjects with type 2 diabetes exhibits impaired capillary formation in response to GROα: involvement of MMPs-2 and -9
Adipocyte · 2022
- Adipose tissue from subjects with type 2 diabetes exhibits impaired capillary formation in response to GROα: involvement of MMPs-2 and -9
Figshare · 2022
- Adipose Tissue from Subjects with Type 2 Diabetes Exhibits Impaired Capillary Formation in Response to GROα: Involvement of MMPs-2 and -9
Figshare · 2022
- p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes
JCI Insight · 2021
- Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathway
Molecular Biology Reports · 2021
- Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes
Frontiers in Physiology · 2020
- Alirocumab offers superior benefits to usual care in treating high-risk patients with type 2 diabetes
2020
- Driven topological transitions in active nematic films
Soft Matter · 2020
- SUN-670 P300 and CBP Are Necessary for Skeletal Muscle Insulin-Stimulated Glucose Uptake
Journal of the Endocrine Society · 2020
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
UNC Libraries · 2020
- Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Diabetes Care · 2019
- 149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)
Diabetes · 2019
- Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Clinical Diabetes · 2019
- 1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)
Diabetes · 2019
- Diabetes Care×28
- Diabetes Obesity and Metabolism×9
- Diabetes×8
- Diabetologia×4
- Diabetes Technology & Therapeutics×3
- C. Jensen
Medicine · University of Michigan
- C. Moak
Medicine · University of Michigan
- C. Friason
Medicine · University of Michigan
- C. Hazlett
Medicine · University of Michigan
- C. Sanders-Jones
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile